Michael ZürcherOct 142 min readINSIGHTSOrphan Drug Designation: Key differences between Switzerland and the EU
Michael ZürcherAug 271 min readSWIZZARD CHAMPIONSUnlock the Secrets to Building a Successful International Biotech HQ!
Michael ZürcherJul 231 min readINSIGHTSExciting news from Swizzard—we’ve just welcomed our 35th client!
Michael ZürcherJul 91 min readINSIGHTSFrom early access to national reimbursement – your partner for Swiss market access
Michael ZürcherMar 191 min readINSIGHTSSuccess factors for foreign players entering the Swiss pharmaceuticals market
Michael ZürcherMay 15, 20242 min readINSIGHTSSwissmedic's 2023 report on human medicines: A leap forward in healthcare innovation
Michael ZürcherApr 10, 20242 min readINSIGHTSSwiss Pharmaceutical Market 2023: Further Growth Achieved
Michael ZürcherNov 22, 20231 min readINSIGHTSNew Opportunity in Swiss Market Access: Accelerated Access to Vital Medicines
Michael ZürcherSep 4, 20232 min readINSIGHTSSwitzerland’s Commitment to Healthcare as a Leader in Health Spending and Patent Application
Michael ZürcherApr 20, 20233 min readINSIGHTSArticle 71 KVV: The case-by-case approach to reimburse pharmaceuticals – a Swiss specialty
Michael ZürcherFeb 15, 20233 min readINSIGHTSMarket Access in Switzerland – or how to include medical breakthroughs on the specialties list
Michael ZürcherSep 14, 20224 min readINSIGHTSSwizzard Insight No. 5: How to bring medical breakthroughs to Switzerland faster
Michael ZürcherFeb 16, 20222 min readINSIGHTSSwizzard Insight No. 4: Project Orbis – how to accelerate your oncology breakthroughs in Switzerland
Michael ZürcherDec 1, 20211 min readINSIGHTSSwizzard Insight No. 3: How to win Switzerland with your medical breakthroughs
Michael ZürcherNov 24, 20212 min readINSIGHTSSwizzard Insight No. 2: The Swiss Federal Office of Public Health (FOPH)
